Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Dazostinag · TAK-676

Small molecule · Agonist of stimulator of interferon genes protein (STING1) · developed by TAKEDA PHARMACEUTICAL CO

Phase 1/2 Most advanced trial (none active)
TAK Developer

What is Dazostinag?

Dazostinag (TAK-676) is an agonist of the STING protein (TMEM173) that is given intravenously. It binds STING and activates the STING pathway in immune cells of the tumor microenvironment, driving pro-inflammatory cytokine and interferon production and a cytotoxic T-lymphocyte response. It is being studied in solid neoplasms.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
TAK-676
Drug type
Small molecule
Targets
stimulator of interferon genes protein (STING1)
Mechanism
Agonist of stimulator of interferon genes protein (STING1)
Pathways
STING pathway, interferon production, cross-presentation of tumor-associated antigens by dendritic cells
Therapy area
Oncology
Developer
TAKEDA PHARMACEUTICAL CO (TAK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
W4RT71M1YD

Conditions studied

Solid Neoplasms

More from TAKEDA PHARMACEUTICAL CO

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the TAK page.

Follow TAK, the company behind Dazostinag

See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TAK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.